Cambrex, a CDMO of small-molecule active pharmaceutical ingredients and drug products, has named Thomas Loewald as the company’s new Chief Executive Officer (CEO) and a member of the company’s Board of Directors, effective September 7, 2020. He is succeeding Steven Klosk as CEO, who is retiring later this month (June 30, 2020) after 28 years with the company.

Mr. Loewald is a 15-year veteran of Thermo Fisher Scientific, where he served in several senior executive roles during his tenure, including Chief Commercial Officer, President of the Analytical Instruments Group, President of the Laboratory Products Group, and President of the Laboratory Equipment Division. He currently serves as President of the Flexibles Division of ProAmpac, a flexible packaging manufacturer. Earlier in his career, he held leadership positions at Tyco International and General Electric. Mr. Loewald currently serves on the Board of Directors of Harvard BioScience, a developer, manufacturer and marketer of scientific instrumentation and related products supporting the life sciences. 

As previously announced, in the interim, the company will be led by an Office of the CEO comprised of Wayne Hewett, Chairman of the Board, Robert Green, Executive Vice President and Chief Financial Officer, and Samantha Hanley, Senior Vice President and General Counsel.

Source: Cambrex